≡ Risteys
R14

Documentation Changelog GitHub Contact & Feedback

Progressive supranuclear ophthalmoplegia (Steele-Richardson-Olszewski)

Endpoint Browser PheWeb

G6_PROGRESSIVE_SUPRANUCLEAR_OPHTHALMOPLEGIA

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

557745

1. Apply sex-specific rule

None

557745

2. Check conditions

None

557745

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ICD-10 — G23.1
  • Cause of death: ICD-10 — G23.1

2 out of 7 registries used, show all original rules.

237

4. Check minimum number of events

None

237

5. Include endpoints

None

237

6. Filter based on genotype QC (FinnGen only)

217

Control definitions (FinnGen only)

Controls for this endpoint are individuals that are not cases.

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

This endpoint is excluded (different definition than used in FinnGen).

-FinnGen-

Key figures

All Female Male
Number of individuals 217 79 138
Unadjusted period prevalence (%) 0.05 0.03 0.06
Median age at first event (years) 75.51 75.83 75.33

-FinnGen-

Age distribution of first events

-FinnGen-

Year distribution of first events

-FinnGen-

Cumulative Incidence Function

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
223
Matched controls
2230
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
G23.1
ICD-10 Finland
Progressive supranuclear ophthalmoplegia [Steele-Richardson-Olszewski]
+∞
319.6
222
*
N04BA02
ATC
levodopa and decarboxylase inhibitor; oral
157.9
307.0
179
56
110
Kela drug reimbursment
Parkinson's disease and comparable movement disrorders
71.6
204.1
122
37
G20
ICD-10 Finland
Parkinson disease
66.1
192.1
116
36
N87
ICPC
Parkinsonism
77.1
154.1
86
18
G25.9
ICD-10 Finland
Extrapyramidal and movement disorder, unspecified
55.3
82.4
48
11
G23.9
ICD-10 Finland
Degenerative disease of basal ganglia, unspecified
119.4
29.5
31
*
S01.0
ICD-10 Finland
Open wound of scalp
6.5
29.4
57
112
R4130
NOMESCO Finland
Speech therapy
10.4
28.5
34
38
L28
ICPC
Limited function/disability (L)
4.6
27.9
106
368
N06DA03
ATC
rivastigmine; oral, transdermal
6.9
26.8
47
83
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
5.8
24.6
53
114
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
4.1
24.0
109
422
D21
ICPC
Swallowing problem
24.6
22.9
32
15
SPAT1229
SPAT
Assessment of need for aid
5.6
22.9
51
113
A28
ICPC
Limited function/disability NOS
4.0
22.8
105
408
N04BC04
ATC
ropinirole; oral
48.8
21.9
26
6
SPAT1216
SPAT
Assessment of functional ability
4.0
20.9
83
288
W01
ICD-10 Finland
Fall on same level from slipping, tripping and stumbling
3.7
20.8
127
586
R26.8
ICD-10 Finland
Other and unspecified abnormalities of gait and mobility
8.2
19.1
27
37
R13
ICD-10 Finland
Dysphagia
5.0
18.5
46
111
N99
ICPC
Neurological disease other
36.4
18.4
23
7
N02AE01
ATC
buprenorphine; parenteral, sublingual, transdermal
3.8
17.8
72
250
F02.39*G20
ICD-10 Finland
Dementia in Parkinson's disease without information on additional symptoms
97.5
16.8
18
*
G04BD12
ATC
mirabegron; oral
3.7
16.6
69
243
R41.8
ICD-10 Finland
Other and unspecified symptoms and signs involving cognitive functions and awareness
3.9
15.5
55
173
AA1AD
NOMESCO Finland
CT of head and brain
3.0
14.8
118
605
N06AX11
ATC
mirtazapine; oral
3.0
14.4
105
511
U04
ICPC
Incontinence urine
4.7
14.4
37
91
N19
ICPC
Speech disorder
17.3
14.3
22
14
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
4.6
14.2
37
92
N04BA03
ATC
levodopa, decarboxylase inhibitor and COMT inhibitor; oral
21.8
14.1
20
10
G25.8
ICD-10 Finland
Other specified extrapyramidal and movement disorders
11.1
13.4
25
25
SPAT1217
SPAT
Assessment of need for services (elderly/care support)
3.9
13.2
45
137
A04
ICPC
Weakness/tiredness general
3.3
13.1
61
228
SPAT1234
SPAT
Support of social functional capacity
4.9
12.8
30
68
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
4.3
12.6
36
96
R53
ICD-10 Finland
Malaise and fatigue
2.8
12.6
91
435
SPAT1245
SPAT
Provision of support and information to patient’s family members
5.0
12.5
29
65
AA5EN
NOMESCO Finland
Brain reseptor or transprot protein distribution isotope imaging
40.0
12.4
15
*
N05AH04
ATC
quetiapine; oral
3.3
12.3
56
205
J18.9
ICD-10 Finland
Pneumonia, unspecified
2.7
12.2
104
539
R5110, ,
SPAT
3.7
12.2
44
139
SPAT1137
SPAT
Taking care of patient’s/customer’s hygiene
3.9
11.4
37
108
J69.0
ICD-10 Finland
Pneumonitis due to food and vomit
10.0
11.3
22
24
SPAT1230
SPAT
Aid fitting and borrowing and monitoring of use
2.9
11.1
65
274
JDB10
NOMESCO Finland
Percutaneous gastrostomy
12.9
11.1
19
16
G21.9
ICD-10 Finland
Secondary parkinsonism, unspecified
45.7
11.0
13
*
N04BD01
ATC
selegiline; oral
13.9
10.9
18
14
SPAT1215
SPAT
Assessment of need for medical rehabilitation
5.7
10.8
21
40
SPAT1222
SPAT
Counselling/guidance promoting independent living
2.9
10.6
64
274
N02AA05
ATC
oxycodone; systemic
2.7
10.6
82
400
N06AB10
ATC
escitalopram; oral
3.1
10.3
50
189
SPAT1231
SPAT
Assessment of adjustments needed in living environment
9.4
10.0
20
23
SPAT1224
SPAT
Implementation of speech therapy rehabilitation plan
17.7
10.0
15
9
A06AD11
ATC
lactulose; oral
2.8
9.7
62
273
N30.0
ICD-10 Finland
Acute cystitis
3.0
9.6
50
197
504
Kela drug reimbursment
Conditions requiring daily forced enteral nutrition
10.2
9.5
18
19
R47.1
ICD-10 Finland
Dysarthria and anarthria
12.2
9.2
16
14
N04BC05
ATC
pramipexole; oral
3.5
9.1
35
114
SPAT1223
SPAT
Implementation of physical therapy rehabilitation plan
2.4
8.9
94
523
R4130, ,
SPAT
52.1
8.7
10
*
N29
ICPC
Neurological sympt/complt other
13.5
8.5
14
11
N28
ICPC
Limited function/disability (N)
9.1
8.5
17
20
N03AE01
ATC
clonazepam; systemic
4.2
8.2
23
60
TAB00
NOMESCO Finland
Lumbar puncture
4.6
7.8
19
44
Z03.3
ICD-10 Finland
Observation for suspected nervous system disorder
3.8
7.8
25
72
SPAT1220
SPAT
Assessment of need for rehabilitation and/or rehabilitation plan
3.6
7.7
26
78
Z50.9
ICD-10 Finland
Care involving use of rehabilitation procedure, unspecified
4.7
7.6
18
41
SPAT1305
SPAT
Counselling and guidance related to physical exercise
3.1
7.5
35
128
P20
ICPC
Memory disturbance
2.4
7.4
65
328
XA800
NOMESCO Finland
Neuropsychological investigation
6.2
7.4
19
33
S01.1
ICD-10 Finland
Open wound of eyelid and periocular area
4.8
7.3
17
38
R25.1
ICD-10 Finland
Tremor, unspecified
6.4
7.2
18
30
UDQ42
NOMESCO Finland
Endoscopic assessment of swallowing function
31.1
7.2
9
*
W19
ICD-10 Finland
Unspecified fall
2.8
7.1
38
150
Z51.5
ICD-10 Finland
Palliative care
2.6
7.0
45
196
TKC20
NOMESCO Finland
Catheterisation of bladder
3.0
7.0
34
128
N04BD02
ATC
rasagiline; oral
17.3
6.8
10
6
SPAT1053
SPAT
Memory test
2.3
6.7
64
334
SPAT1254
SPAT
Administration of medicine
2.4
6.6
51
242
S06.0
ICD-10 Finland
Concussion
2.8
6.6
37
150
SPAT1226
SPAT
Implementation of occupational therapy rehabilitation plan
6.5
6.6
16
26
S00.0
ICD-10 Finland
Superficial injury of scalp
6.5
6.6
16
26
Z50.8
ICD-10 Finland
Care involving use of other rehabilitation procedures
3.1
6.6
29
103
S01XA20
ATC
artificial tears and other indifferent preparations; ophthalmic
2.0
6.4
119
800
WYA30
NOMESCO Finland
Treatment of a patient needing special arrangements
3.4
6.4
24
77
XF606
NOMESCO Finland
Ortostatic test
27.5
6.3
8
*
N06AX16
ATC
venlafaxine; oral
2.8
6.0
32
126

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
123
719
2.58
10.97
4.7
4.7
—
—
—
0
0
123
730
2.53
10.47
4.7
3.5
—
—
—
0
0
16
19
8.98
7.96
1.0
1.0
193.91
331.33
ng/l
—
11
9
16
19
8.98
7.96
1.0
1.0
725.30
514.90
ng/l
—
10
10
85
473
2.29
7.82
2.0
1.8
1262.45
1157.76
nmol/l
0.32
60
359
114
739
2.11
6.94
2.6
2.2
271.84
343.29
u/l
0.22
107
696
174
1387
2.16
5.40
6.1
5.0
—
1.61
—
0
5
13
28
4.86
4.44
1.0
1.3
—
—
—
0
0
142
1095
1.82
4.35
5.9
6.6
1.22
1.21
mmol/l
0.83
129
1002
9
15
6.20
3.85
3.2
2.0
—
—
—
0
0
76
503
1.78
3.81
5.1
4.2
—
0.33
—
0
9
134
1048
1.70
3.60
5.6
4.9
34.90
34.52
g/l
0.29
123
985
149
1203
1.72
3.52
7.1
7.4
1.22
1.21
mmol/l
1.82
125
1026
101
747
1.64
3.26
4.3
4.5
7.40
7.40
ph
0.86
78
535
8
15
5.49
3.22
1.0
1.1
133.38
134.73
nmol/l
—
8
15
56
819
0.58
3.14
4.0
4.4
8.72
11.47
mg/mmol
0.22
35
533
132
1056
1.61
3.02
2.4
2.3
92.55
94.23
pmol/l
0.17
71
576
112
862
1.60
3.01
4.9
4.1
6.41
6.23
ph
0.99
63
460
55
794
0.59
2.86
3.4
3.6
45.36
61.81
mg/l
0.41
38
535
135
1107
1.56
2.62
5.5
4.5
0.00
6.60
estimate
0.50
25
246
7
15
4.78
2.62
1.4
1.2
—
—
—
0
0
56
790
0.61
2.59
3.3
3.5
7.74
7.30
mmol/l
0.27
40
642
14
57
2.55
2.50
1.5
1.5
206.71
273.92
ug/g
—
7
35
6
12
5.10
2.42
1.0
1.1
—
—
—
0
0
72
521
1.56
2.41
1.8
1.9
472.63
13539622.45
pmol/l
0.50
59
421
90
688
1.52
2.34
4.2
3.7
0.25
0.44
e6/l
1.42
68
519
37
566
0.58
2.33
2.7
4.1
—
—
—
0
0
34
205
1.78
2.28
2.1
2.5
27.34
34.35
u/l
1.01
29
169
5
9
5.65
2.22
1.2
1.0
1.79
1.79
mmol/l
—
5
9
131
1092
1.48
2.18
5.5
4.5
0.00
0.00
estimate
-0.00
20
238
133
1115
1.48
2.13
5.6
4.5
0.00
1.35
estimate
0.51
24
225
99
794
1.44
1.94
4.1
3.8
92.11
121.72
e6/l
0.13
73
619
73
552
1.48
1.94
3.6
3.5
—
0.00
—
0
13
104
852
1.41
1.77
4.9
4.6
99.25
107.16
e6/l
0.08
72
629
96
778
1.41
1.73
2.4
3.7
2.34
2.35
mmol/l
0.30
83
699
22
127
1.81
1.71
2.2
4.0
—
—
—
0
0
29
182
1.68
1.71
2.4
3.6
7.43
7.42
ph
1.73
24
151
150
1320
1.42
1.64
5.6
5.4
6.58
6.92
mmol/l
2.13
143
1270
198
1842
1.67
1.62
26.6
20.9
34.25
26.98
mg/l
2.33
184
1583
7
26
2.75
1.59
1.1
2.8
—
—
—
0
0
173
1582
1.42
1.36
8.2
9.0
78.79
81.73
u/l
0.41
159
1492
20
121
1.72
1.36
1.7
1.9
1.72
4.80
ug/l
0.61
15
107
53
402
1.42
1.35
4.4
3.5
2.66
1.66
e6/l
0.36
27
210
167
1801
0.71
1.35
6.6
7.9
39.11
41.00
mmol/mol
2.73
149
1650
0
40
0.00
1.34
0.0
1.6
—
—
—
0
0
5
18
2.82
1.29
1.0
1.1
—
—
—
0
0
26
172
1.58
1.27
2.7
2.9
6.22
6.09
ph
0.25
18
128
70
566
1.35
1.21
2.7
2.9
6.96
4.33
e6/l
0.69
63
518
46
593
0.72
1.20
2.6
3.2
347.32
367.80
umol/l
0.66
38
506
87
729
1.32
1.18
4.3
5.9
—
—
—
0
0
5
112
0.43
1.16
1.6
1.3
—
—
—
0
0
26
179
1.51
1.09
2.3
4.2
—
—
—
0
0
62
500
1.33
1.09
2.9
3.6
527.53
551.49
mosm/kgh2o
0.37
53
440
154
1409
1.30
1.02
4.1
4.2
15.89
15.17
pmol/l
2.72
132
1234
20
132
1.57
1.01
1.2
1.2
—
—
—
0
0
90
771
1.28
1.01
1.9
1.8
17.60
20.53
nmol/l
1.12
81
615
0
30
0.00
0.98
0.0
1.2
—
—
—
0
0
58
471
1.31
0.97
6.8
4.7
1.02
1.02
kg/l
0.68
39
319
6
29
2.10
0.90
1.2
1.0
—
—
—
0
0
170
1796
0.78
0.83
4.5
5.8
4.25
4.32
mmol/l
0.35
150
1620
169
1785
0.78
0.81
4.4
5.7
1.40
1.42
mmol/l
0.34
148
1596
10
58
1.76
0.81
3.4
2.9
39.60
34.90
umol/l
—
10
52
83
721
1.24
0.80
2.4
2.6
—
—
—
0
0
81
704
1.24
0.77
3.8
2.4
54.18
68.88
u/l
0.93
73
644
23
168
1.41
0.75
4.5
3.6
—
—
—
0
0
6
108
0.54
0.74
1.2
1.3
—
—
—
0
0
59
498
1.25
0.73
3.0
3.2
2.44
2.46
mmol/l
0.95
51
448
162
1713
0.80
0.73
3.9
4.8
1.22
1.25
mmol/l
0.28
138
1521
28
360
0.75
0.72
1.8
2.7
2.22
1.81
%
0.63
23
322
200
1927
1.37
0.69
31.7
25.9
3.94
4.02
mmol/l
5.17
195
1890
92
819
1.21
0.68
6.2
4.6
0.00
0.02
estimate
0.68
15
201
25
190
1.36
0.66
3.1
4.1
75.00
91.58
ng/l
0.47
19
166
129
1190
1.20
0.65
21.8
17.8
1.33
1.33
inr
0.00
113
1002
180
1717
1.25
0.62
5.3
5.4
1.87
2.06
mu/l
1.24
156
1516
76
855
0.83
0.62
3.8
4.5
—
—
—
0
0
73
641
1.21
0.62
2.4
2.3
2.80
3.05
mg/l
0.56
56
555
5
30
1.68
0.62
1.2
2.0
87.06
88.85
%
—
5
30
22
286
0.74
0.61
1.4
1.4
1.96
20.71
u/ml
—
8
93
55
473
1.22
0.57
4.8
4.1
62.00
323.93
ng/l
2.16
48
418
53
612
0.82
0.57
6.3
6.5
—
—
—
0
0
8
122
0.64
0.56
1.1
1.3
—
—
—
0
0
6
37
1.64
0.56
1.0
1.1
—
—
—
0
0
22
279
0.77
0.53
5.4
3.9
7.37
7.38
ph
0.29
12
167
48
411
1.21
0.52
2.3
3.1
0.83
0.82
mmol/l
0.14
42
392
6
40
1.51
0.52
1.2
1.1
—
—
—
0
0
107
985
1.17
0.51
5.1
4.6
43.82
42.12
ng/l
0.04
90
813
18
234
0.75
0.51
6.2
6.7
9.22
11.55
mmol/l
1.00
18
225
177
1835
0.83
0.49
5.3
6.8
2.35
2.46
mmol/l
0.92
155
1648
7
45
1.57
0.49
1.4
3.6
5.71
11.00
pmol/l
—
7
45
113
1048
1.16
0.48
4.3
6.1
0.04
0.04
e9/l
0.10
93
876
175
1815
0.83
0.48
5.1
6.2
6.01
6.18
mmol/l
1.58
153
1620
18
231
0.76
0.47
3.3
3.1
5.49
4.43
kpa
1.04
18
221
200
1945
1.27
0.47
36.4
31.5
239.57
233.67
e9/l
0.59
194
1902
200
1945
1.27
0.47
36.4
31.4
4.33
4.39
e12/l
1.11
193
1894
200
1945
1.27
0.47
36.3
31.5
7.40
6.90
e9/l
0.89
193
1895
7
51
1.38
0.44
1.0
1.1
—
—
—
0
0
7
51
1.38
0.44
1.0
1.4
—
—
—
0
0
103
956
1.14
0.42
4.2
6.4
60.20
59.81
%
0.10
98
901
5
33
1.53
0.41
1.4
1.3
565.60
1868.80
e6/l
—
5
20
0
16
0.00
0.41
0.0
1.4
—
—
—
0
0
0
16
0.00
0.41
0.0
1.6
—
1.51
—
0
16
0
17
0.00
0.41
0.0
2.5
—
0.82
—
0
17
104
969
1.14
0.40
4.4
6.3
2.48
2.74
%
0.59
99
895
0
18
0.00
0.40
0.0
1.6
—
0.86
—
0
18
104
972
1.13
0.38
4.5
6.5
8.50
9.17
%
1.47
98
901
111
1042
1.13
0.37
4.3
6.1
0.56
0.63
e9/l
2.87
89
866
112
1056
1.12
0.34
4.3
6.2
2.14
1.78
e9/l
0.33
93
913
187
1915
0.85
0.33
12.8
14.0
23.55
24.42
u/l
0.22
180
1847
21
174
1.23
0.33
6.0
4.3
—
—
—
0
0
119
1129
1.12
0.32
4.2
3.3
66.84
57.39
u/l
0.27
103
1034
29
250
1.18
0.31
1.4
1.8
—
—
—
0
0
7
54
1.31
0.30
1.0
1.1
—
—
—
0
0
7
55
1.28
0.30
4.4
4.6
1.96
2.06
mmol/l
—
7
37
7
55
1.28
0.30
1.3
1.1
—
—
—
0
0
16
195
0.81
0.30
1.6
1.5
—
—
—
0
0
51
462
1.13
0.30
1.4
1.7
1.92
1.71
mg/l
0.10
36
382
21
177
1.21
0.28
1.3
2.2
12.22
11.91
nmol/l
0.06
16
151
26
224
1.18
0.28
3.9
4.1
7.36
7.36
ph
0.03
17
154
17
204
0.82
0.28
1.1
1.5
—
—
—
0
0
68
631
1.11
0.27
6.8
4.6
0.00
0.01
estimate
0.50
23
216
103
977
1.10
0.27
4.5
6.5
24.38
24.81
%
0.12
97
910
37
331
1.14
0.26
5.9
6.9
7.41
7.41
ph
0.01
24
198
28
245
1.16
0.26
1.4
1.3
537.14
520.00
titre
—
7
59
23
265
0.85
0.25
5.4
4.0
2.26
1.56
mmol/l
0.51
23
216
64
595
1.11
0.24
4.8
4.1
0.00
0.13
estimate
0.50
20
189
43
391
1.12
0.24
1.4
1.2
0.85
0.84
u/ml
0.00
11
98
25
284
0.87
0.23
3.3
4.7
2.49
51.13
ug/l
1.12
19
245
123
1182
1.09
0.23
6.2
7.0
12.77
12.58
umol/l
0.06
111
1122
120
1152
1.09
0.23
6.1
10.2
4.52
4.45
e9/l
0.10
100
993
44
402
1.12
0.23
2.5
2.7
23.27
21.55
%
0.28
39
370
5
40
1.26
0.22
1.2
1.6
22.28
28.63
g/l
—
5
35
38
345
1.12
0.22
2.3
2.0
—
—
—
0
0
112
1074
1.09
0.22
4.3
6.3
0.19
0.19
e9/l
0.04
94
914
36
396
0.89
0.22
4.1
6.0
—
—
—
0
0
0
11
0.00
0.21
0.0
1.0
—
0.23
—
0
6
0
11
0.00
0.21
0.0
1.5
—
—
—
0
0
0
10
0.00
0.21
0.0
1.7
—
—
—
0
0
0
12
0.00
0.21
0.0
1.2
—
—
—
0
0
0
12
0.00
0.21
0.0
1.2
—
—
—
0
0
49
453
1.10
0.21
2.4
2.6
11.79
12.08
umol/l
0.08
43
414
0
13
0.00
0.21
0.0
1.1
—
—
—
0
0
0
13
0.00
0.21
0.0
1.5
—
0.64
—
0
7
0
14
0.00
0.20
0.0
1.7
—
—
—
0
0
0
14
0.00
0.20
0.0
3.5
—
49.78
—
0
9
14
165
0.84
0.20
1.4
1.5
—
—
—
0
0
6
50
1.21
0.20
1.2
1.1
—
—
—
0
0
19
217
0.86
0.19
2.0
2.6
7.81
7.84
ug/l
0.00
13
192
24
214
1.14
0.18
4.6
2.3
—
—
—
0
0
103
991
1.07
0.18
2.7
2.9
—
—
estimate
—
0
0
56
595
0.92
0.17
3.0
3.5
0.85
0.86
ug/l
0.03
44
423
8
71
1.13
0.16
1.3
1.5
—
—
—
0
0
25
274
0.90
0.14
5.0
4.0
6.02
5.68
kpa
0.67
25
263
19
170
1.13
0.14
1.6
1.5
—
—
—
0
0
23
210
1.11
0.12
2.6
1.9
431.29
397.87
nmol/l
0.42
17
198
13
147
0.88
0.12
2.8
2.7
1.39
1.11
%
0.39
13
147
14
125
1.13
0.10
2.6
3.2
—
—
—
0
0
24
258
0.92
0.10
2.3
3.4
5.15
5.27
e9/l
0.03
14
219
13
145
0.89
0.09
2.8
2.7
0.58
0.64
%
0.33
13
145
21
226
0.92
0.08
9.7
8.6
—
—
—
0
0
28
296
0.94
0.07
1.5
1.4
—
—
—
0
0
6
75
0.79
0.07
1.2
1.2
—
—
—
0
0
83
810
1.04
0.07
2.0
2.3
—
—
—
0
0
38
365
1.05
0.06
1.4
1.4
2.34
2.77
g/l
0.78
20
205
89
906
0.97
0.05
12.1
14.2
0.00
0.00
e9/l
0.64
65
739
148
1465
1.03
0.05
30.3
26.8
13.85
13.97
%
0.61
148
1453
13
120
1.09
0.05
2.2
2.5
—
—
—
0
0
24
250
0.96
0.03
1.5
1.5
—
—
—
0
0
25
260
0.96
0.03
1.2
1.3
—
—
—
0
0
11
102
1.08
0.03
1.9
1.9
—
—
—
0
0
12
128
0.93
0.02
2.3
4.1
36.94
36.89
°c
0.15
12
128
88
870
1.02
0.02
2.8
3.0
231.18
163.27
ug/l
0.49
77
788
39
382
1.03
0.01
6.3
6.4
104.15
104.15
mmol/l
0.00
39
382
29
296
0.98
0.00
1.3
1.2
—
—
—
0
0
16
161
0.99
0.00
1.6
1.5
—
—
—
0
0
102
1019
1.00
0.00
5.2
6.5
2.55
3.25
ug/l
0.64
87
899
51
513
0.99
0.00
1.3
1.3
—
—
—
0
0
10
96
1.04
0.00
1.1
1.3
—
—
—
0
0
19
192
0.99
0.00
1.6
1.5
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
5.62
—
0
5
0
5
0.00
0.00
0.0
3.2
—
1.06
—
0
5
6
65
0.92
0.00
14.8
13.3
—
—
—
0
0
0
5
0.00
0.00
0.0
2.8
—
2.20
—
0
5
0
5
0.00
0.00
0.0
1.0
—
25.00
—
0
5
0
5
0.00
0.00
0.0
2.4
—
—
—
0
0
0
5
0.00
0.00
0.0
6.0
—
5.00
—
0
5
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
39.83
—
0
6
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
-0.00
0.0
5.3
—
23.74
—
0
7
0
6
0.00
-0.00
0.0
1.0
—
16.28
—
0
6
6
62
0.97
-0.00
1.3
1.1
—
3.00
—
0
6
0
7
0.00
-0.00
0.0
5.7
—
46.71
—
0
7
0
9
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.7
—
—
—
0
0
0
6
0.00
-0.00
0.0
3.7
—
—
—
0
0
5
57
0.87
-0.00
1.0
1.1
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.1
—
—
—
0
0

Mortality – FinRegistry

↥

This endpoint is excluded (different definition than used in FinnGen).

Relationships between endpoints

↥

Index endpoint: G6_PROGRESSIVE_SUPRANUCLEAR_OPHTHALMOPLEGIA – Progressive supranuclear ophthalmoplegia (Steele-Richardson-Olszewski)

GWS hits: -

This endpoint is excluded (different definition than used in FinnGen).